{
    "nctId": "NCT03126110",
    "briefTitle": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
    "officialTitle": "A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Malignancies, Metastatic Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 145,
    "primaryOutcomeMeasure": "Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.\n* Phase 1: Subjects with advanced or metastatic solid tumors.\n* Phase 1: Subjects who have disease progression after treatment with available therapies.\n* Phase 2: Subjects with advanced or metastatic cervical cancer, gastric cancer (including stomach, esophageal, and GEJ), SCCHN, PD-1 refractory SCCHN and PD-1/PD-L1 relapsed melanoma.\n* Presence of measurable disease based on RECIST v1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.\n\nExclusion Criteria:\n\n* Laboratory and medical history parameters not within the Protocol-defined range\n* Prior treatment with any tumor necrosis factor super family agonist.\n* Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.\n* Has not recovered to \u2264 Grade 1 from toxic effects of prior therapy.\n* Active autoimmune disease.\n* Known active central nervous system metastases and/or carcinomatous meningitis.\n* Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.\n* Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.\n* Known history of human immunodeficiency virus (HIV; HIV 1/2 antibodies).",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}